EA201390971A1 - ИМИДАЗО[5,1-f][1,2,4]ТРИАЗИНЫ ДЛЯ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ РАССТРОЙСТВ - Google Patents

ИМИДАЗО[5,1-f][1,2,4]ТРИАЗИНЫ ДЛЯ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ РАССТРОЙСТВ

Info

Publication number
EA201390971A1
EA201390971A1 EA201390971A EA201390971A EA201390971A1 EA 201390971 A1 EA201390971 A1 EA 201390971A1 EA 201390971 A EA201390971 A EA 201390971A EA 201390971 A EA201390971 A EA 201390971A EA 201390971 A1 EA201390971 A1 EA 201390971A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
triazins
imidazo
treatment
neurological disorders
Prior art date
Application number
EA201390971A
Other languages
English (en)
Other versions
EA022586B1 (ru
Inventor
Томас Аллен Чэппи
Джон Майкл Хамфри
Патрик Роберт Верхоест
Эдди Янг
Кристофер Джон Хилал
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45755439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201390971(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Publication of EA201390971A1 publication Critical patent/EA201390971A1/ru
Publication of EA022586B1 publication Critical patent/EA022586B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Настоящее изобретение относится к соединениям формулы (I)и их фармацевтически приемлемым солям, к способам их получения, к промежуточным соединениям, используемым для их получения, и к композициям, содержащим эти соединения; и к применению этих соединений в способе лечения заболевания или состояния, выбранного из группы, состоящей из расстройств центральной нервной системы, нарушений познавательной способности, шизофрении, деменции и других расстройств, у млекопитающего.
EA201390971A 2011-02-23 2012-02-09 ИМИДАЗО[5,1-f][1,2,4]ТРИАЗИНЫ ДЛЯ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ РАССТРОЙСТВ EA022586B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161445617P 2011-02-23 2011-02-23
PCT/IB2012/050589 WO2012114222A1 (en) 2011-02-23 2012-02-09 IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS

Publications (2)

Publication Number Publication Date
EA201390971A1 true EA201390971A1 (ru) 2014-02-28
EA022586B1 EA022586B1 (ru) 2016-01-29

Family

ID=45755439

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390971A EA022586B1 (ru) 2011-02-23 2012-02-09 ИМИДАЗО[5,1-f][1,2,4]ТРИАЗИНЫ ДЛЯ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ РАССТРОЙСТВ

Country Status (30)

Country Link
US (2) US8598155B2 (ru)
EP (1) EP2681218A1 (ru)
JP (1) JP5543039B2 (ru)
KR (1) KR101548443B1 (ru)
CN (1) CN103391941A (ru)
AP (1) AP2013007070A0 (ru)
AR (1) AR085304A1 (ru)
AU (1) AU2012221828C1 (ru)
BR (1) BR112013021366A2 (ru)
CA (1) CA2825699A1 (ru)
CL (1) CL2013002125A1 (ru)
CO (1) CO6751271A2 (ru)
CR (1) CR20130371A (ru)
CU (1) CU20130107A7 (ru)
DO (1) DOP2013000194A (ru)
EA (1) EA022586B1 (ru)
EC (1) ECSP13012892A (ru)
GT (1) GT201300206A (ru)
IL (1) IL227716A0 (ru)
MA (1) MA34922B1 (ru)
MX (1) MX2013009684A (ru)
NI (1) NI201300071A (ru)
PE (1) PE20140236A1 (ru)
SG (1) SG192576A1 (ru)
TN (1) TN2013000349A1 (ru)
TW (1) TWI469983B (ru)
UA (1) UA106692C2 (ru)
UY (1) UY33916A (ru)
WO (1) WO2012114222A1 (ru)
ZA (1) ZA201306348B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2659070C2 (ru) * 2014-04-23 2018-06-28 Дарт Нейросайенс (Кайман) Лтд. ЗАМЕЩЕННЫЕ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2825699A1 (en) * 2011-02-23 2012-08-30 Thomas Allen Chappie Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
MX2015015163A (es) 2013-05-02 2016-02-22 Pfizer Derivados de imidazo-triazina como inhibidores de pde10.
EP3087060B1 (en) 2013-12-23 2020-05-13 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as pde2 inhibitors
US9849132B2 (en) 2014-01-08 2017-12-26 Intra-Cellular Therapies, Inc. Products and pharmaceutical compositions
TWI568737B (zh) 2014-11-05 2017-02-01 達特神經科學（開曼）有限責任公司 作為ｐｄｅ２抑制劑之經取代的５－甲基－［１，２，４］三唑并［１，５－ａ］嘧啶－２－胺化合物
US10105349B2 (en) 2014-12-06 2018-10-23 Intra-Cellular Therapies, Inc. Organic compounds
KR102557603B1 (ko) 2014-12-06 2023-07-19 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
CN104525240A (zh) * 2014-12-10 2015-04-22 河北工业大学 硝酸铁作为催化剂在苯与羟胺盐反应一步法制苯胺反应中的应用方法
JP2017538769A (ja) 2014-12-22 2017-12-28 ファイザー・インク プロスタグランジンｅｐ３受容体の拮抗薬
TWI713497B (zh) * 2015-02-26 2020-12-21 南韓商愛思開生物製藥股份有限公司 咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
EP3285581B1 (en) 2015-03-26 2021-08-11 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as pde2 inhibitors
US10195201B2 (en) 2015-05-05 2019-02-05 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as PDE2 inhibitors
WO2016183741A1 (en) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Pyrimidinone amide compounds as pde2 inhibitors
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
EP3313852B1 (en) 2015-06-25 2021-01-20 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
WO2017004134A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
BR112018008431A2 (pt) * 2015-11-02 2018-11-06 Janssen Pharmaceutica Nv composto de [1,2,4]triazolo[1,5-a]pirimidin-7-il
CN105669680B (zh) * 2016-03-24 2018-02-23 南京药捷安康生物科技有限公司 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂
WO2018065288A1 (de) 2016-10-07 2018-04-12 Bayer Cropscience Aktiengesellschaft 2-[2-phenyl-1-(sulfonylmethyl)vinyl]-imidazo[4,5-b]pyridin-derivate und verwandte verbindungen als schädlingsbekämpfungsmittel im pflanzenschutz
ES2855032T3 (es) 2016-11-02 2021-09-23 Janssen Pharmaceutica Nv Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de PDE2
AU2017353313C1 (en) 2016-11-02 2022-06-09 Janssen Pharmaceutica Nv (1,2,4)triazolo(1,5-a)pyrimidine compounds as PDE2 inhibitors
SG11201903892UA (en) 2016-11-02 2019-05-30 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
KR102628073B1 (ko) 2017-01-10 2024-01-22 바이엘 악티엔게젤샤프트 해충 방제제로서의 헤테로사이클 유도체
UY37556A (es) 2017-01-10 2018-07-31 Bayer Ag Derivados heterocíclicos como pesticidas
WO2019101970A1 (en) 2017-11-23 2019-05-31 Oslo University Hospital Hf Treatment of tachycardia
CN108640923A (zh) * 2018-07-09 2018-10-12 湖南天地恒制药有限公司 一种托法替布关键中间体的制备方法
US20220064169A1 (en) * 2018-10-23 2022-03-03 Intra-Cellular Therapies, Inc. Novel compounds
US11492362B1 (en) 2022-02-17 2022-11-08 King Abdulaziz University Pyridine derivatives for the treatment of hyperproliferative diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4035893A (en) * 1991-12-17 1993-07-19 Upjohn Company, The 3-substituted imidazo (1,5-a) and imidazo (1,5-a)-triazolo (1,5-c) quinoxalines and quinazolines with cns activity
YU59100A (sh) * 1999-10-11 2003-10-31 Pfizer Inc. Postupak za dobijanje pirazolo (4,3-d) pirimidin-7-ona-3-piridilsulfonil jedinjenja i njihova intermedijera
DE10130167A1 (de) 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
DE10230605A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
DE10230604A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
WO2005041957A1 (en) * 2003-10-29 2005-05-12 Pfizer Products Inc. Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors
CN102924458B (zh) 2004-04-02 2014-11-05 Osi制药有限责任公司 6,6-双环取代的杂双环蛋白激酶抑制剂
AR053090A1 (es) 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
DE102004038328A1 (de) * 2004-08-06 2006-03-16 Bayer Healthcare Ag Neue Verwendungen von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
EP1812439B2 (en) * 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7671050B2 (en) * 2005-01-05 2010-03-02 Nycomed Gmbh Triazolophthalazines
PL1841757T3 (pl) 2005-01-07 2010-10-29 Pfizer Prod Inc Heteroaromatyczne związki chinoliny i ich zastosowanie jako inhibitorów PDE10
EP2385053B1 (en) 2005-11-17 2013-10-02 OSI Pharmaceuticals, Inc. Intermediates for the preparation of fused bicyclic mTOR inhibitors
EP1981890A2 (en) 2006-01-25 2008-10-22 OSI Pharmaceuticals, Inc. UNSATURATED mTOR INHIBITORS
US7651687B2 (en) 2006-03-13 2010-01-26 Osi Pharmaceuticals, Inc. Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
PT2526933E (pt) 2006-09-22 2015-06-23 Pharmacyclics Inc Inibidores da tirosina-quinase de bruton
EP2178563A2 (en) 2007-07-06 2010-04-28 OSI Pharmaceuticals, Inc. Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mtorc2
US7683575B2 (en) 2007-07-18 2010-03-23 Tesla Motors, Inc. Method and apparatus for identifying and disconnecting short-circuited battery cells within a battery pack
MX2010010300A (es) 2008-03-19 2010-10-26 Osi Pharm Inc Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
JP2011520970A (ja) 2008-05-19 2011-07-21 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換されたイミダゾピラジン類およびイミダゾトリアジン類
CN102471292A (zh) 2009-07-09 2012-05-23 Osi药物有限责任公司 取代的3-氨基-5-氧代-4,5-二氢-[1,2,4]三氮烯的方法
EP2531509B1 (en) 2010-02-03 2016-10-05 Incyte Holdings Corporation Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
CA2825699A1 (en) * 2011-02-23 2012-08-30 Thomas Allen Chappie Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2659070C2 (ru) * 2014-04-23 2018-06-28 Дарт Нейросайенс (Кайман) Лтд. ЗАМЕЩЕННЫЕ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
RU2659070C9 (ru) * 2014-04-23 2018-08-24 Дарт Нейросайенс (Кайман) Лтд. ЗАМЕЩЕННЫЕ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2

Also Published As

Publication number Publication date
CR20130371A (es) 2013-09-18
JP5543039B2 (ja) 2014-07-09
TW201247673A (en) 2012-12-01
CO6751271A2 (es) 2013-09-16
CA2825699A1 (en) 2012-08-30
KR101548443B1 (ko) 2015-08-28
DOP2013000194A (es) 2014-01-31
BR112013021366A2 (pt) 2016-09-13
NI201300071A (es) 2014-02-12
AR085304A1 (es) 2013-09-18
JP2014506589A (ja) 2014-03-17
MX2013009684A (es) 2013-10-28
TWI469983B (zh) 2015-01-21
US8598155B2 (en) 2013-12-03
PE20140236A1 (es) 2014-03-14
IL227716A0 (en) 2013-09-30
AP2013007070A0 (en) 2013-08-31
SG192576A1 (en) 2013-09-30
CL2013002125A1 (es) 2013-12-20
WO2012114222A1 (en) 2012-08-30
US9200000B2 (en) 2015-12-01
AU2012221828C1 (en) 2015-10-01
EP2681218A1 (en) 2014-01-08
KR20130132612A (ko) 2013-12-04
UA106692C2 (ru) 2014-09-25
CN103391941A (zh) 2013-11-13
TN2013000349A1 (fr) 2015-01-20
ECSP13012892A (es) 2013-10-31
US20120214791A1 (en) 2012-08-23
UY33916A (es) 2012-09-28
NZ613373A (en) 2015-04-24
US20140066622A1 (en) 2014-03-06
GT201300206A (es) 2015-02-19
AU2012221828B2 (en) 2015-05-28
EA022586B1 (ru) 2016-01-29
CU20130107A7 (es) 2013-09-27
ZA201306348B (en) 2014-04-30
MA34922B1 (fr) 2014-02-01

Similar Documents

Publication Publication Date Title
EA201390971A1 (ru) ИМИДАЗО[5,1-f][1,2,4]ТРИАЗИНЫ ДЛЯ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ РАССТРОЙСТВ
SG195085A1 (en) Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
UA113186C2 (xx) Макроциклічні інгібітори lrrk2 кінази
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
SG10201804791UA (en) 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
EA201200373A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
EA201270480A1 (ru) Новые соединения
EA201001159A1 (ru) Конденсированные гетероциклические производные и их применение
GEP20166483B (en) Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament
EA201390766A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
MX336224B (es) Quinolinas sustituidas y su uso como medicamentos.
EA201390398A1 (ru) Арилсульфонамиды для лечения заболеваний цнс
EA201270610A1 (ru) Хинуклидиновые соединения как альфа-7 лиганды ацетилхолинового рецептора
EA201890922A1 (ru) Циклические простоэфирные производные пиразоло[1,5-а]пиримидин-3-карбоксамида
EA201491026A1 (ru) Производные 3-фенилизохинолин-1(2h)-она в качестве ингибиторов parp-1
WO2012103282A3 (en) Methods and compositions for treating alzheimer's disease
MY165623A (en) 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
MX2014014808A (es) Compuestos triciclicos como inhibidores de kat ii.
EA201491878A8 (ru) Замещенные ксантиновые производные
MY182553A (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
EA201390327A1 (ru) Гетероциклильные соединения в качестве лигандов гистаминовых hрецепторов
PH12014502780A1 (en) Azetidine and piperidine compounds useful as pde10 inhibitors

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU